Sign in

CIK 0001714899

  • Large accelerated filer

Denali Therapeutics Inc.

Sign in to watch
Ticker
DNLI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
463872213
Phone
+1 650-866-8547
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Planned sale Chief Medical Officer sold 22,458 shares at an average $24.49 ($549,928)
  2. 4 Open-market sale COFO and Secretary sold 2,272 shares at $22.89 ($52,006)
  3. 4 Open-market sale Chief Medical Officer sold 2,337 shares at $22.89 ($53,494)
  4. 4 Planned sale Director sold 30,688 shares at an average $22.11 ($678,660)
  5. 4 Planned sale Director sold 3,080 shares at an average $22.14 ($68,204)
  6. 4 Planned sale Director sold 1,458 shares at $21.73 ($31,682)
  7. 4 Grant or award Director acquired 5,967 shares (grant or award)
  8. 4 Grant or award Director acquired 5,967 shares (grant or award)
  9. 4 Grant or award Director acquired 5,967 shares (grant or award)
  10. 4 Grant or award Director acquired 5,967 shares (grant or award)
  11. 4 Grant or award Director acquired 5,967 shares (grant or award)
  12. 4 Grant or award Director acquired 5,967 shares (grant or award)
  13. 4 Grant or award Director acquired 5,967 shares (grant or award)
  14. 4 Grant or award Director acquired 5,967 shares (grant or award)
  15. 4 Grant or award Director acquired 5,967 shares (grant or award)
  16. 4 Planned sale Director sold 1,674 shares at $20.39 ($34,133)
  17. 4 Planned sale Director sold 1,666 shares at $18.29 ($30,471)
  18. 4 Planned sale Director sold 92,500 shares at $20.50 ($1,896,250)
  19. 4 Gift President and CEO gave 40,000 shares (gift)
  20. 4 Planned sale Director sold 1,666 shares at $20.10 ($33,487)

Page 4 of 22 · 436 filings